Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. (CLDX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · CLDX · as of Mar 31, 2025
Ownership Breakdown
180
Institutional Holders
▼ 11 vs Q4
$1.34B
Total Inst. Value
▼ $525.25M vs Q4
66.54M
Shares Outstanding
freeFloat 92.18%
73.63M
13F Shares Held
▼ 58,652 vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
CLDX largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
WELLINGTON MANAGEMENT GROUP LLP in vitro & in vivo diagnostic substances | 8.35M | 12.58% | 12.58% | $151.63B | May 13, 2025 | ▼ 621.7K |
KYNAM CAPITAL MANAGEMENT, LP in vitro & in vivo diagnostic substances | 6.50M | 9.79% | 9.79% | $117.97B | May 15, 2025 | ▲ 1.44M |
BLACKROCK, INC. in vitro & in vivo diagnostic substances | 5.52M | 8.32% | 8.32% | $100.26B | May 2, 2025 | ▲ 43.5K |
FMR LLC in vitro & in vivo diagnostic substances | 5.38M | 8.10% | 8.10% | $97.65B | May 12, 2025 | ▲ 522.4K |
VANGUARD GROUP INC in vitro & in vivo diagnostic substances | 3.90M | 5.87% | 5.87% | $70.76B | May 9, 2025 | ▲ 16.4K |
EVENTIDE ASSET MANAGEMENT, LLC in vitro & in vivo diagnostic substances | 3.75M | 5.66% | 5.66% | $68.18B | May 15, 2025 | ▲ 1.5K |
PRICE T ROWE ASSOCIATES INC /MD/ in vitro & in vivo diagnostic substances | 3.41M | 5.14% | 5.14% | $61.90B | May 14, 2025 | ▼ 146.6K |
COMMODORE CAPITAL LP in vitro & in vivo diagnostic substances | 3.20M | 4.82% | 4.82% | $58.08B | May 15, 2025 | ▲ 3.20M |
BELLEVUE GROUP AG in vitro & in vivo diagnostic substances | 3.07M | 4.63% | 4.63% | $55.75B | May 14, 2025 | — held |
STATE STREET CORP in vitro & in vivo diagnostic substances | 2.81M | 4.23% | 4.23% | $50.94B | May 15, 2025 | ▼ 428.6K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
27
Increased
+8.87M shares1
New Positions
first time holders19
Decreased
−4.14M shares0
Sold Out
fully exitedNet shares change (top 50)
+4.73M
+8.87M / −4.14M
Net new holders
+9
1 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
CLDX insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
6
Buy transactions
7
Sell transactions
0.86
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Jimenez Freddy A. SVP & GENERAL COUNSEL | Dec 4, 2025 | Sale | 4,166 | $29.09 | $121.2K | 30.8K | Form 4 ↗ |
Wright Richard M. Former Officer | Nov 13, 2025 | Sale | 49,298 | $24.00 | $1.18M | 20.8K | Form 4 ↗ |
Lawver Teri L SVP & Chief Commercial Officer | Nov 10, 2025 | Award | 100,000 | $22.67 | $2.27M | 100.0K | Form 4 ↗ |
Jimenez Freddy A. SVP & GENERAL COUNSEL | Aug 13, 2025 | Sale | 341 | $23.95 | $8.2K | 35.4K | Form 4 ↗ |
Jimenez Freddy A. SVP & GENERAL COUNSEL | Aug 13, 2025 | Sale | 430 | $25.41 | $10.9K | 35.0K | Form 4 ↗ |
Cavanaugh Sarah SVP OF CORP AFFAIRS & ADMIN. | Jun 5, 2025 | Award | 78,000 | $19.53 | $1.52M | 78.0K | Form 4 ↗ |
Crowley Elizabeth SR. VP & CPDO | Jun 5, 2025 | Award | 85,000 | $19.53 | $1.66M | 85.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Celldex Therapeutics, Inc. (CLDX) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 7.82%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Celldex Therapeutics, Inc. is WELLINGTON MANAGEMENT GROUP LLP, holding approximately 8.35 million shares — equal to 12.58% of outstanding shares — as of March 31, 2025.
A total of 180 institutional investors currently hold CLDX stock, with a combined institutional value of approximately $1.34 billion as of the most recent 13F filing period.
Frequently asked questions
CLDX ownershipCelldex Therapeutics, Inc. (CLDX) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is WELLINGTON MANAGEMENT GROUP LLP with a 12.58% stake. Company insiders hold 7.82%. Data sourced from SEC Form 13F as of March 31, 2025.